Emerging Ubiquitin and Autophagy Targets


Autophagy and the ubiquitin-proteasome system (UPS) are the two major pathways responsible for protein degradation and maintenance of cellular homeostasis. They consist of well-controlled, selective mechanisms for intracellular protein degradation and turnover. New understanding of the role and molecular mechanisms involved in the dysregulation of autophagy and ubiquitin pathways has revealed its underlying role in cancer, CNS, immunology and other diseases. However, the diversity of substrates and the multi-step processes involved, make it difficult to target these pathways for therapeutic intervention. In recent years, the development of high-quality chemical probes, small molecule modulators, assays and screening platforms have helped identify novel autophagy and ubiquitin targets for drug discovery. Cambridge Healthtech Institute’s conference on Emerging Ubiquitin and Autophagy Targets will bring together a diverse group of chemists and biologists to discuss the promise and challenges in this area of research. This conference will be followed by one that focuses exclusively on targeted protein degradation using proteolysis-targeting chimeric molecules (PROTACs) and other molecular entities for hijacking the ubiquitin system.

Preliminary Agenda


Probes and Assays to Discover E3 Ligase Inhibitors, Activators, and Protein Degraders
Alexander Statsyuk, PhD, Assistant Professor, Department of Pharmacological and Pharmaceutical Sciences, University of Houston

Use of Tip60 PROTACs in Cereblon-Knockin Mice
Wayne W. Hancock, MD, PhD, Professor, Pathology and Chief of Transplant Immunology, Children’s Hospital of Philadelphia and University of Pennsylvania

Solving a 60-Year Mystery: SALL4 Mediates Teratogenicity as a Thalidomide-Dependent Substrate of Cereblon
Mary Matyskiela, PhD, Principal Scientist, Structural and Chemical Biology, Celgene

Engineering Protein-Protein Interactions to Probe and Rewire Ubiquitin Signaling
Wei Zhang, PhD, Assistant Professor, Molecular and Cellular Biology, University of Guelph


ULK3 Kinase as a Key Regulator of Cancer Associated Fibroblast Conversion
Sandro Goruppi, PhD, Instructor in Dermatology, Harvard Medical School, Cutaneous Biology Research Center, Massachusetts General Hospital

Drugging the Fbw7 E3 Ligase with a Combined Computational and Fragment-Based Approach
Carles Galdeano, PhD, Serra Hunter Professor, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, University of Barcelona

Targeting Autophagy in Cancer Treatment
Andrew Thorburn DPhil, Chair, Department of Pharmacology, University of Colorado, School of Medicine


Potent Small Molecule Parkin Activators for Treating Neurodegenerative Diseases
Suresh Kumar, PhD, Senior Director R&D, Progenra Inc.

A Neurodevelopmental Disorder Caused by USP7 Haploinsufficiency
Ryan Potts, PhD, Associate Member, Department of Cell and Molecular Biology, St. Jude Children’s Research Hospital



For more details on the conference, please contact:
Tanuja Koppal, PhD

Conference Director

Cambridge Healthtech Institute

Email: tkoppal@healthtech.com


For partnering and sponsorship information, please contact:
Rod Eymael

Manager, Business Development

Cambridge Healthtech Institute

Phone: (+1) 781-247-6286
Email: reymael@healthtech.com